Navigation Links
Napo in Medical News

Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals

... SAN FRANCISCO, Dec. 10 /PRNewswire/ -- napo Pharmaceuticals, Inc. ("Napo") is pleased to annou... of $500,000 for the purchase of 250,000 shares of napo common stock; as well as regulatory and sales mile...llaboration Agreement) will include a reference to napo as the licensor and will include Napo's logo and r...

Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer

... napo Pharmaceuticals, Inc., which focuses on the develo...r an FDA Fast Track designation. On Jan. 16, 2007, napo met with the FDA under the Special Protocol Assess...ive design of its ADVENT trial. On March 14, 2007, napo announced it had received approval from the princi...
Napo in Medical Technology

Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

... SAN FRANCISCO, Sept. 22 /PRNewswire/ -- napo Pharmaceuticals (LSE: NAPL/NAPU) today announces p...tic, azithromycin, and rehydration therapy. Both napo and ICDDR, B, upon receipt of additional funding, ...al Institutes of Allergy and Infectious Disease. napo is currently conducting a Phase 3 trial for crofel...

Napo Presents at ISPOR Meeting in Toronto

...um of anti-retroviral drugs. We are pleased to see napo taking the initiative to develop this new instrume...rhea." For more information please contract: napo Pharmaceuticals, Inc. Lisa Conte, Chief Executive...ector, Clinical Operations 1+ 760 918 5718 About napo Pharmaceuticals, Inc. ...

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

...n travelers in Mexico and Jamaica with crofelemer, napo is investigating the regulatory pathway to file an...diarrhea in people living with HIV/AIDS (CRO-HIV). napo is targeting an NDA filing for CRO-HIV around the end of the year. napo has exclusive worldwide rights to crofelemer in al...

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea

...ritories, Glenmark will pay ascending royalties to napo on sales of crofelemer for these indications. Gl...3 2008." For more information please contact: napo Pharmaceuticals, Inc. Lisa Conte, Chief Executive... 7466 5000 Tim Anderson, Mary-Jane Johnson About napo Pharmaceuticals, Inc. ...

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.

...CO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- napo Pharmaceuticals, Inc., , which focuses on the deve... licensed crofelemer for the d-IBS indication from napo in June 2004. Trine has worldwide development and ... For more information please contact: napo Pharmaceuticals, Inc Lisa Conte, Chief Execut...
Napo in Biological Technology

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

...MMD trial. This was partially offset by the absence of license income from napo and the revenues lost from our withdrawal of IPLEX(TM) in the short stature...00,000 loss on investments represents the full write down on the prior year napo investment during 2008. As of December 31, 2008, we had total cash, ca...

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

...m Napo, was recorded as part of our agreement with napo in 2007. For the nine months ended September 30,...ially offset by the absence of license income from napo and the revenues lost from our withdrawal of IPLEX... investments represents the full write down of the napo investment during the first nine months of 2008. ...

Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)

...ar NEW YORK, Sept. 25 /PRNewswire-USNewswire/ -- napo Pharmaceuticals, Inc., ("Napo") of South San Franc...uch as HIV/AIDS and cholera. As part of the CAP, napo and Direct Relief International ("DRI") have formed an alliance whereby napo will provide CRO-PED at cost for distribution thro...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

... absence of license income from our agreement with napo Pharmaceuticals Inc., ("Napo") from which we recei...ially offset by the absence of license income from napo and the revenues lost from our withdrawal of IPLEX...ss on investments represents the write down on the napo investment during the first half of 2008. Intere...

Insmed Announces First Quarter 2008 Financial Results

...and Tercica Inc., and the absence of license income from our agreement with napo Pharmaceuticals Inc., ("Napo") from which we received a milestone payment i...y a milestone payment from Napo, was recorded as part of our agreement with napo in 2007. Interest income in the first quarter of 2008 at $279,000 was sli...

IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference

... Group Ltd. Hoersholm, Denmark Santaris BioPharmaceutical Pharmaceutical California, USA napo Pharmaceutical BioPharmaceutical Wurmlingen, Paradigm Spine, LLC Devices Germany Tokyo, Japan EyePlusPlus,...

Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results

...ng period of 2006. This increase was due to improvements in the cost recovery from our EAP and the receipt of licensing income from our agreement with napo Pharmaceuticals Inc., ("NAPO"), combined with increased sales of IPLEX(TM) during the first quarter of 2007. The net loss for the 12 months ended De...

M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer

...pany as Chief Medical Officer. Prior to joining Ocera, Dr. Harris held the position of Chief Medical Officer and Vice President of Clinical Affairs at napo Pharmaceuticals. Dr. Harris has extensive experience in gastrointestinal diseases as well as clinical and regulatory operations. "We are delighted b...
Other Tags
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... biophysics textbook and it describes how life functions and ... into biological systems and provides an understanding of the ... how our genes make proteins that control the dynamics ... an organism. It quantifies the principles of life and ... on both large and small scales. The book is ...
(Date:10/15/2014)... Fred Alt will be awarded the 44th Rosenstiel Award ... for his pioneering research exploring the mechanisms of genomic ... cancer cells. Alt is the second alumnus to win ... Nobel Prize in 2003. , Alt is the Charles ... at Harvard Medical School and an investigator at the ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
Other Contents